Published in Retrovirology on April 29, 2015
Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine (ISS T-002) | NCT00751595
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology (2016) 1.42
The Startling Properties of Fibroblast Growth Factor 2: How to Exit Mammalian Cells without a Signal Peptide at Hand. J Biol Chem (2015) 0.82
HIV-Tat Protein Forms Phosphoinositide-dependent Membrane Pores Implicated in Unconventional Protein Secretion. J Biol Chem (2015) 0.79
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol (2016) 0.79
Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Front Immunol (2015) 0.77
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep (2017) 0.77
A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice. Sci Rep (2016) 0.76
HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology (2016) 0.76
Molecular and Genetic Characterization of HIV-1 Tat Exon-1 Gene from Cameroon Shows Conserved Tat HLA-Binding Epitopes: Functional Implications. Viruses (2016) 0.75
Inhibition of regulated cell death by cell-penetrating peptides. Cell Mol Life Sci (2016) 0.75
Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. BMC Infect Dis (2016) 0.75
HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology. BMC Infect Dis (2016) 0.75
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Dose sparing with intradermal injection of influenza vaccine. N Engl J Med (2004) 5.14
Targeting early infection to prevent HIV-1 mucosal transmission. Nature (2010) 5.05
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (2007) 4.84
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 4.47
Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol (2008) 4.25
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (2009) 4.19
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol (1993) 3.68
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol (2006) 3.59
Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med (2003) 3.48
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis (2009) 3.39
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature (2011) 3.08
Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature (1994) 3.05
Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science (2001) 3.02
Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol (2001) 2.93
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
HIV-1 Tat affects the programming and functionality of human CD8⁺ T cells by modulating the expression of T-box transcription factors. AIDS (2014) 2.54
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med (1999) 2.27
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog (2014) 2.03
HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology (2009) 2.02
Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science (1997) 1.97
Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev (2010) 1.85
Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol (2009) 1.84
The evolutionary dynamics of human endogenous retroviral families. Annu Rev Genomics Hum Genet (2006) 1.79
Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 1.68
Switching effective antiretroviral therapy: a review. Clin Infect Dis (2002) 1.66
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol (1998) 1.52
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
The potential of CD4 T-cell memory. Immunology (2010) 1.40
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol (2002) 1.29
The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect (2012) 1.24
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis (2005) 1.23
The T-cell response to HIV. Cold Spring Harb Perspect Med (2012) 1.20
Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci U S A (1997) 1.20
Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J (2010) 1.18
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol (2004) 1.13
Therapeutic vaccines against HIV infection. Hum Vaccin Immunother (2012) 1.11
Innate immune control of HIV. Cold Spring Harb Perspect Med (2012) 1.09
B-cell subset alterations and correlated factors in HIV-1 infection. AIDS (2013) 1.08
Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.07
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am (2009) 1.06
Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J Leukoc Biol (2010) 1.03
The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine (2007) 1.02
Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol (2013) 1.01
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol (2009) 1.00
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol (2011) 1.00
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res (2008) 0.97
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine (2009) 0.97
Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther (2009) 0.96
Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis (2003) 0.95
The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine (2009) 0.95
The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS (2008) 0.95
Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother (2003) 0.95
HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) (2010) 0.94
Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol (2014) 0.93
Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquir Immune Defic Syndr (1991) 0.92
Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets (2012) 0.92
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology (2014) 0.92
HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One (2012) 0.91
HIV reservoirs: the new frontier. AIDS Rev (2011) 0.87
The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. PLoS One (2013) 0.85
Impact of HIV type 1 DNA levels on spontaneous disease progression: a meta-analysis. AIDS Res Hum Retroviruses (2011) 0.84
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles. J Gene Med (2009) 0.83
Emerging therapies for food allergy. J Clin Invest (2014) 0.83
HIV reservoir dynamics in the face of highly active antiretroviral therapy. AIDS Patient Care STDS (2014) 0.83
Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. J Antimicrob Chemother (2013) 0.82
A real time PCR platform for the simultaneous quantification of total and extrachromosomal HIV DNA forms in blood of HIV-1 infected patients. PLoS One (2014) 0.78
Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. AIDS (2014) 0.77